MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.47
+0.69
+1.83%
Opening 12:15 06/24 EDT
OPEN
38.11
PREV CLOSE
37.78
HIGH
38.94
LOW
38.05
VOLUME
517.04K
TURNOVER
--
52 WEEK HIGH
64.37
52 WEEK LOW
34.43
MARKET CAP
5.42B
P/E (TTM)
-10.9299
1D
5D
1M
3M
1Y
5Y
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Benzinga · 23h ago
Global Antisense & RNAi Therapeutics Market Report 2021-2025 & 2030
/PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 5d ago
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (...
PR Newswire - PRF · 06/10 22:05
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor functionA NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintain...
GlobeNewswire · 06/10 11:30
Antisense & RNAi Therapeutics Global Market Report 2021: COVID 19 Growth And Change to 2030
Reportlinker.com announces the release of the report "Antisense & RNAi Therapeutics Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090629/?utm_source=GNW
GlobeNewswire · 06/09 09:23
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 13:39
10 Best Pharmaceutical Stocks to Buy According to Cathie Wood
In this article we discuss the 10 best pharmaceutical stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of Cathie Wood’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharmaceutical St...
Insider Monkey · 06/02 13:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IONS. Analyze the recent business situations of Isis Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IONS stock price target is 57.83 with a high estimate of 114.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 547
Institutional Holdings: 134.06M
% Owned: 95.10%
Shares Outstanding: 140.96M
TypeInstitutionsShares
Increased
126
7.20M
New
53
2.51M
Decreased
107
5.47M
Sold Out
64
2.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+1.11%
Key Executives
Chairman/Director
Joseph Loscalzo
Chief Executive Officer/Director
Brett Monia
Chief Financial Officer/Executive Vice President
Elizabeth Hougen
Executive Vice President/Chief Scientific Officer
C. Frank Bennett
Executive Vice President/General Counsel
Patrick O'Neil
Executive Vice President
Onaiza Cadoret-Manier
Executive Vice President
Richard Geary
Executive Vice President
Eugene Schneider
Executive Vice President
Eric Swayze
Other/Director
B. Lynne Parshall
Lead Director/Independent Director
Joseph Wender
Director
Allene Diaz
Independent Director
Spencer Berthelsen
Independent Director
Michael Hayden
Independent Director
Joan Herman
Independent Director
Joseph Klein
Independent Director
Frederick Muto
Independent Director
Peter Reikes
No Data
  • All
  • Financials
  • Insiders
More
About IONS
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.